Eli Van Allen Profile picture
LA | @Stanford '03 | @UCLA MD '07 | @UCSF IM '10 | Now: @DanaFarber @broadinstitute @harvardmed clinical computational oncology! Discl.: https://t.co/XkFZSwd04f
Aug 29, 2018 13 tweets 9 min read
A thread on our latest look at cancer genomics + immune checkpoint blockade → congrats @diana_miao, Claire, @NIVokes et al!

Thx @SU2C @BroadIgnite @HHMINEWS @theNCI for supporting this & the ppl doing it @NatureGenet @DanaFarber @broadinstitute

rdcu.be/5iVz [1/n] We analyzed every tumor-normal exome from patients getting immune checkpoint blockade (ICB) we could get & integrated w/ clinical outcomes for biological and clinical exploration → lots of technical pain here + open questions re: defining clinical benefit
Aug 9, 2018 4 tweets 2 min read
Lots of discussion whether broad cancer NGS testing is good/bad given @JAMAOnc article below. Tbh I'm far more interested in some general issues it exposes re: prospectively testing the precision oncology hypothesis:

jamanetwork.com/journals/jama/… [1/4] 1) NGS testing w/o companion (early phase?) clinical trial network & mid-trial adjustments for when new approvals arise creates a ‘last mile’ problem that reduces potential impact. Can a precision oncology trial have experimental Rx access and be changed in real time? [2/4]
Apr 25, 2018 6 tweets 3 min read
Reflecting on the recent/heated “hype vs. hope” precision oncology debates: It’s not “vs.” → real hope it engenders & current limitations are simultaneously true. This tension mirrors so much of oncology, as @Bob_Wachter elegantly points out here:
nytimes.com/2018/04/19/opi… [1/n] Thankfully, @DHymanMD captured this critical point clearly, here:
Apr 3, 2018 11 tweets 12 min read
A twitter explainer for our latest #teamscience study rdcu.be/KwgV congrats Josh @stephanie_mul @dliu_ccb @nikolausschultz Arul @CharlesSawyers et al @PCFnews @SU2C @DanaFarber @broadinstitute @MSKCC_OncoNotes @NatureGenet [1/n] I've been lucky to grow up academically around many #prostatecancer scientific 'big machers' & helped with early cancer genomic maps over the last 5+ years, e.g.:
1) rdcu.be/Kw8d (@Chris_Barbieri1)
2) cell.com/cell/fulltext/…
3) cell.com/abstract/S0092… (@NCIgenomics)
Mar 2, 2018 10 tweets 6 min read
A twitter explainer on our latest study, Inherited DNA Repair Defects in Colorectal Cancer – congrats @s_aldubayan @MattYurgelun @SapnaSyngal et al! @DanaFarber @broadinstitute @DamonRunyon @AJHGNews authors.elsevier.com/a/1Web9geWqOxr There’s an established heritability for colorectal cancer hovering around 30%, though only roughly 5-10% is explained by known syndromes involving genes like APC, MSH2, and PTEN, among others – the rest is so-called “missing heritability”